Rapid reversal of hepatic steatosis, and reduction of muscle triglyceride, by rosiglitazone: MRI/S studies in Zucker fatty rats
| Autor: | Paul D. Hockings, C. N. Toseland, Kumar Changani, David G. Reid, J. A. Osborne, P. O'Brien, N. Saeed, R. E. Buckingham, Jeffrey M. Birmingham |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Agonist
chemistry.chemical_classification medicine.medical_specialty Triglyceride medicine.diagnostic_test medicine.drug_class business.industry Endocrinology Diabetes and Metabolism Skeletal muscle Peroxisome proliferator-activated receptor Magnetic resonance imaging medicine.disease chemistry.chemical_compound Endocrinology medicine.anatomical_structure chemistry Internal medicine Internal Medicine medicine Steatosis Thiazolidinedione Rosiglitazone business medicine.drug |
| Zdroj: | Diabetes, Obesity and Metabolism. 5:234-243 |
| ISSN: | 1462-8902 |
| DOI: | 10.1046/j.1463-1326.2003.00268.x |
| Popis: | Aim: This study aimed to chart the time course and durability of the effects of rosiglitazone, a potent thiazolidinedione-based peroxisome proliferator-activated receptor γ agonist, on hepatic steatosis and intramyocellular lipid in an animal model of obesity, the Zucker Fatty (ZF) rat. Methods and Results: Rosiglitazone (3 mg/kg/day p.o.) significantly reduced both liver fat content (by 59%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text